Journal of Neuro-Oncology

, Volume 114, Issue 3, pp 329–338 | Cite as

Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study

  • Hee Jo Baek
  • Hyeon Jin Park
  • Ki Woong Sung
  • Soo Hyun Lee
  • Jung Woo Han
  • Kyung Nam Koh
  • Ho Joon Im
  • Hyoung Jin Kang
  • Kyung Duk Park
Clinical Study


The present study evaluated the feasibility and effectiveness of myeloablative high-dose chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors (CNS-GCTs). Eleven patients with non-germinomatous germ cell tumors and nine patients with germinomas were enrolled. Patients received between two and eight cycles of conventional chemotherapy prior to HDCT/autoSCT with or without radiotherapy. Overall, 16 patients proceeded to the first HDCT/autoSCT, and nine proceeded to the second HDCT/autoSCT. CTE (carboplatin–thiotepa–etoposide) and cyclophosphamide–melphalan (CM) regimens were used for the first and second HDCT, respectively. Toxicities during HDCT/autoSCT were acceptable, and there were no treatment-related deaths. Twelve patients experienced relapse or progression; however, four patients with germinomas remain alive after subsequent RT. Therefore, a total of 12 patients (four NGGCTs and eight germinomas) remain alive with a median follow-up of 47 months (range 22–90) after relapse or progression. The probability of 3-year overall survival was 59.1 ± 11.2 % (36.4 ± 14.5 % for NGGCTs vs. 88.9 ± 10.5 % for germinomas, P = 0.028). RT, particularly craniospinal RT, was associated with a better tumor response prior to HDCT/autoSCT and a better final outcome. In conclusion, HDCT/autoSCT was feasible, and survival rates were encouraging. Further study with a larger cohort of patients is needed to elucidate the role of HDCT/autoSCT in the treatment of relapsed or progressed CNS-GCTs.


Central nervous system germ cell tumor High-dose chemotherapy Autologous stem cell transplantation 



This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (No. 0520300).

Conflict of interest

We declare that there is no competing financial interest in relation to this work.


  1. 1.
    Aoyama H, Shirato H, Kakuto Y, Inakoshi H, Nishio M, Yoshida H, Hareyama M, Yanagisawa T, Watarai J, Miyasaka K (1998) Pathologically-proven intracranial germinoma treated with radiation therapy. Radiother Oncol 47:201–205PubMedCrossRefGoogle Scholar
  2. 2.
    Bamberg M, Kortmann RD, Calaminus G, Becker G, Meisner C, Harms D, Göbel U (1999) Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol 17:2585–2592PubMedGoogle Scholar
  3. 3.
    Matsutani M (2001) Japanese pediatric brain tumor study group. Combined chemotherapy and radiation therapy for CNS germ cell tumors; the Japanese experience. J Neurooncol 54:311–316PubMedCrossRefGoogle Scholar
  4. 4.
    Robertson PL, DaRosso RC, Allen JC (1997) Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy. J Neurooncol 32:71–80PubMedCrossRefGoogle Scholar
  5. 5.
    Ogawa K, Toita T, Nakamura K, Uno T, Onishi H, Itami J, Shikama N, Saeki N, Yoshii Y, Murayama S (2003) Treatment and prognosis of patients with intracranial nongerminomatous malignant germ cell tumors: a multi-institutional retrospective analysis of 41 patients. Cancer 98:369–376PubMedCrossRefGoogle Scholar
  6. 6.
    Kretschmar C, Kleinberg L, Greenberg M, Burger P, Holmes E, Wharam M (2007) Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 48:285–291PubMedCrossRefGoogle Scholar
  7. 7.
    Merchant TE, Sherwood SH, Mulhern RK, Rose SR, Thompson SJ, Sanford RA, Kun LE (2000) CNS germinoma: disease control and long-term functional outcome for 12 children treated with craniospinal irradiation. Int J Radiat Oncol Biol Phys 46:1171–1176PubMedCrossRefGoogle Scholar
  8. 8.
    Sawamura Y, Ikeda JL, Tada M, Shirato H (1999) Salvage therapy for recurrent germinomas in the central nervous system. Br J Neurosurg 13:376–381PubMedCrossRefGoogle Scholar
  9. 9.
    Modak S, Gardner S, Dunkel IJ, Balmaceda C, Rosenblum MK, Miller DC, Halpern S, Finlay JL (2004) Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol 22:1934–1943PubMedCrossRefGoogle Scholar
  10. 10.
    Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG (2007) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group study. J Clin Oncol 27:1007–1013CrossRefGoogle Scholar
  11. 11.
    Marachelian A, Butturini A, Finlay J (2008) Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transpl 41:167–172CrossRefGoogle Scholar
  12. 12.
    Sung KW, Yoo KH, Cho EJ, Koo HH, Lim do H, Shin HJ, Ahn SD, Ra YS, Choi ES, Ghim TT (2007) High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 48:408–415PubMedCrossRefGoogle Scholar
  13. 13.
    Sung KW, Lim do H, Son MH, Lee SH, Yoo KH, Koo HH, Kim JH, Suh YL, Joung YS, Shin HJ (2013) Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma. Neuro Oncol 15:352–359PubMedCrossRefGoogle Scholar
  14. 14.
    Kalifa C, Hartmann O, Demeocq F, Vassal G, Couanet D, Terrier-Lacombe MJ, Valteau D, Brugieres L, Lemerle J (1992) High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 9:227–233PubMedGoogle Scholar
  15. 15.
    Mahoney DH Jr, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H (1996) High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 14:382–388PubMedGoogle Scholar
  16. 16.
    Graham ML, Herndon JE 2nd, Casey JR, Chaffee S, Ciocci GH, Krischer JP, Kurtzberg J, Laughlin MJ, Longee DC, Olson JF, Paleologus N, Pennington CN, Friedman HS (1997) High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 15:1814–1823PubMedGoogle Scholar
  17. 17.
    Foreman NK, Schissel D, Le T, Strain J, Fleitz J, Quinones R, Giller R (2005) A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol 71:181–187PubMedCrossRefGoogle Scholar
  18. 18.
    Biassoni V, Massimono M, Gandola L, Spreafico E, Seregni M, Terenziani E, Pignoli R, Luksch F, Pallotti M, Casanova C, Meazza G, Cefalo A, Ferrari D, Polastri M, Podda F, Fossati-Bellani (2006) The role of high dose chemotherapy in the treatment of central nervous system germ cell tumours [abstract]. Haematol Rep 2:1Google Scholar
  19. 19.
    Merchant TE, Davis BJ, Sheldon JM, Leibel SA (1998) Radiation therapy for relapsed CNS germinoma after primary chemotherapy. J Clin Oncol 16:204–209PubMedGoogle Scholar
  20. 20.
    De Giorgi U, Rosti G, Slavin S, Yaniv I, Harousseau JL, Ladenstein R, Demirer T, Dini G (2005) Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours. Br J Cancer 93:412–417PubMedCrossRefGoogle Scholar
  21. 21.
    Calaminus G, Patte C (2002) Experience within the SIOP CNS GCT 96 trial/SFOP studies with HDC/SCR in patients with CNS germ cell tumours and further implications for high risk patients [abstract 54]. Bone Marrow Transpl 30:34Google Scholar
  22. 22.
    Frappaz D, Patte C, Peciulyte V, Baranzelli MC, Apapetite C, Kalifa C (2006) High dose vp16-thiotepa (HD VP-TTP) with PBSC rescue in relapsing intra cranial non germinomatous germ cell tumors (ICNGGCT): the SFCE retrospective experience [abstract]. Haematol Rep 2:6Google Scholar
  23. 23.
    Patte C, Frappaz D, Peciulyte V, Baranzelli MC, Pichon F, Coze C, Apapetite C, Kalifa C (2006) High dose vp16-thiotepa (HD VP-TTP) with PBSC rescue in relapsing intra cranial germinomas (ICG): the SFCE retrospective experience [abstract]. Haematol Rep 2:12Google Scholar
  24. 24.
    Bouffet Eric (2010) The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors. Pediatr Blood Cancer 54:644–646PubMedCrossRefGoogle Scholar
  25. 25.
    Finlay J, Stahl R, Haduong J, Dhall G, Torkildson J, Gardner S, Allen J (2011) Outcome of patients with recurrent central nervous system germ cell tumor: a retrospective study, 2003–2010 [abstract]. Pediatr Blood Cancer 57:727Google Scholar
  26. 26.
    da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J (2010) Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer 54:377–383PubMedCrossRefGoogle Scholar
  27. 27.
    Kadota RP, Mahoney DH, Doyle J, Duerst R, Friedman H, Holmes E, Kun L, Zhou T, Pollack IF (2008) Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer 51:675–678PubMedCrossRefGoogle Scholar
  28. 28.
    Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Weinstein J, Rademaker A, Schaefer C, Evans L, Fouts M, Goldman S (2010) A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. J Neurooncol 97:247–255PubMedCrossRefGoogle Scholar
  29. 29.
    Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH, Lee SK, Kim J, Lim DH, Suh YL, Kim DW (2007) Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant 40:37–45PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Hee Jo Baek
    • 1
  • Hyeon Jin Park
    • 2
  • Ki Woong Sung
    • 3
  • Soo Hyun Lee
    • 3
  • Jung Woo Han
    • 4
  • Kyung Nam Koh
    • 5
  • Ho Joon Im
    • 5
  • Hyoung Jin Kang
    • 6
  • Kyung Duk Park
    • 6
  1. 1.Department of PediatricsChonnam National University Medical School, Chonnam National University Hwasun HospitalGwangjuRepublic of Korea
  2. 2.Center for Pediatric OncologyNational Cancer CenterGoyangRepublic of Korea
  3. 3.Department of Pediatrics, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  4. 4.Department of Pediatrics, Severance HospitalYonsei University College of MedicineSeoulRepublic of Korea
  5. 5.Department of Pediatrics, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulRepublic of Korea
  6. 6.Department of Pediatrics, Cancer Research InstituteSeoul National University College of MedicineSeoulRepublic of Korea

Personalised recommendations